drugset / Trial / NCT05543369

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

NCT05543369

Phase 1 Completed 48 enrolled Ipsen
Non-randomizedParallel-groupOpen-labelOther

Summary

This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.

Timeline

Start
2022-09-19
Primary completion
2023-03-10
Completion
2023-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Elafibranor Small molecule 80 mg Oral

Indications

No indication recorded.